Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.
about
Interferon beta for secondary progressive multiple sclerosisPersonalized medicine in multiple sclerosis: hope or reality?The topographical model of multiple sclerosis: A dynamic visualization of disease courseA Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future PerspectivesThe mechanism of action of interferon-β in relapsing multiple sclerosisEFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapsesThe immunopathology of multiple sclerosis: an overviewThe retrovirus/superantigen hypothesis of multiple sclerosis.Walking impairment in patients with multiple sclerosis: exercise training as a treatment option.A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology.Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis.The role of MRI in the evaluation of secondary progressive multiple sclerosis.Sex hormones: a role in the control of multiple sclerosis?Quantification of normal-appearing white matter tract integrity in multiple sclerosis: a diffusion kurtosis imaging study.Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential?Estimating Time to Event From Longitudinal Categorical Data: An Analysis of Multiple Sclerosis ProgressionMRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.Getting the balance right: a randomised controlled trial of physiotherapy and Exercise Interventions for ambulatory people with multiple sclerosis.Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.Real-life walking impairment in multiple sclerosis: preliminary comparison of four methods for processing accelerometry data.Effect of catalpol on remyelination through experimental autoimmune encephalomyelitis acting to promote Olig1 and Olig2 expressions in mice.Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.Geographic variations of multiple sclerosis prevalence in France: The latitude gradient is not uniform depending on the socioeconomic status of the studied population.Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US surveyCognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysisImpact of multiple sclerosis relapses on progression diminishes with timeThe impact of multiple sclerosis onset symptom on cardiac repolarization17beta-estradiol protects male mice from cuprizone-induced demyelination and oligodendrocyte loss.Evidence for a two-stage disability progression in multiple sclerosisThe natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disabilityClinical characteristics of multiple sclerosis in Kuwait: data from the new MS registry of Amiri Hospital.Gender effect on neurodegeneration and myelin markers in an animal model for multiple sclerosisLong term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique.Lessons for clinical trials from natalizumab in multiple sclerosis.Aggressive multiple sclerosis: proposed definition and treatment algorithm.Sex differences in autoimmune diseases.Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
P2860
Q24203879-0526C5F1-D719-4261-8F63-CB34110126E6Q27025933-D8F9E957-1D24-4960-AA49-3C52B635B751Q27312133-98480C3C-17B6-4C1A-A7E4-B378E5381659Q28068709-44DCDE2E-BCD9-4AB5-8BBF-2F531FE3BD27Q28239752-4633D645-730D-4C8E-AF5B-B3E8D681E94BQ28284851-2CDC549C-A8CF-4A56-99CE-4B51206CD9A6Q28295115-03FE548B-8019-450A-A3CD-0043F03B5D8FQ30317136-FFED8EBB-BFB5-48F6-B26E-89069B8A5FE9Q30433850-BCD9B537-F407-4672-B641-902089430A02Q30525646-B148CB34-E429-4937-98A3-BEF5EDDE7728Q30712257-589C8D96-9876-4AB3-BEC5-6955FFCCCCDFQ30983016-EEA7358A-8EF9-4901-BBCC-ED24058D4CF1Q31033345-75D370DB-9CD4-4B4B-8C3D-C75737FA77B3Q31037759-0498B818-A9E8-4590-82D9-A20B6D2D91DCQ31081056-A616E1CB-A192-493B-A940-E9A3D186E2FDQ31117462-672E99E5-AF4D-400B-880A-DCCE32D80119Q31141962-5D580BF2-18A6-4540-96C6-2376275C1A9DQ33289264-8F5DD49A-AF3E-43CF-B42C-9523A217EAD6Q33392874-D664E2FC-985F-402B-84AB-99432ED2DE4EQ33449002-8633CE85-8CDA-401F-AC65-9D36063E626BQ33483034-3ECE1290-35D5-41B9-9EC2-4EEE811FED4DQ33565842-EDD0B51C-BA0A-4B27-A4D1-5346A91B9B71Q33599581-DFC7C261-993F-4EAA-A8ED-6BC20484D089Q33630050-B194035F-A21D-4D69-BD9B-C556BD1ABD4CQ33638157-A38B49CF-C27D-46CB-A12C-43F992042D42Q33692773-219B877B-C964-4E3A-912D-4DFC924EF229Q33719214-8E90D323-3E61-49BF-B0D3-1408952BF3A2Q33761190-0D65CA2D-C2D4-4A40-8CD3-239D7381C648Q33898204-C7484F13-3668-4052-B6CA-B9ACA86C1AF8Q33917429-D195F81B-F137-4B36-A93D-681EB815F265Q33938006-8C8EE3D2-F122-4326-A563-C2C709CA6145Q33944184-87AD653C-1F9E-4C6A-A41B-59D094B81623Q33944200-2776A012-2625-4FEA-96BC-CB7BB7FB9674Q34045441-6D60246A-FA57-49D5-A442-D38B834445A6Q34138065-E59D4DE0-A1D9-4B97-8865-C47D7AC52A7FQ34288517-87F8F984-48B4-46FC-A9A9-A350AC2B3378Q34367044-5C609FD8-5C82-4A87-AAD1-C9A17E3963E0Q34478828-AFA9BEFD-B562-4555-83A9-D78E095A7754Q34498866-E76DA418-AE3B-4807-B76A-C94571F05184Q34631940-F62C7285-6EED-40A0-804B-009F2BDB7CE2
P2860
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Early clinical predictors and ...... sclerosis: an amnesic process.
@en
Early clinical predictors and ...... sclerosis: an amnesic process.
@nl
type
label
Early clinical predictors and ...... sclerosis: an amnesic process.
@en
Early clinical predictors and ...... sclerosis: an amnesic process.
@nl
prefLabel
Early clinical predictors and ...... sclerosis: an amnesic process.
@en
Early clinical predictors and ...... sclerosis: an amnesic process.
@nl
P2093
P356
P1433
P1476
Early clinical predictors and ...... sclerosis: an amnesic process.
@en
P2093
Christian Confavreux
Patrice Adeleine
Sandra Vukusic
P304
P356
10.1093/BRAIN/AWG081
P407
P577
2003-04-01T00:00:00Z